Trials / Withdrawn
WithdrawnNCT04542434
Niclosamide in COVID-19
A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Entero Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niclosamide Oral Tablet | Niclosamide tablets 400 mg 3 times daily for 14 days |
| DRUG | Placebo | Matching placebo tablets 3 times daily for 14 days |
Timeline
- Start date
- 2022-01-20
- Primary completion
- 2022-01-20
- Completion
- 2022-01-20
- First posted
- 2020-09-09
- Last updated
- 2022-02-21
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04542434. Inclusion in this directory is not an endorsement.